Great Point Partners LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Great Point Partners LLC reported 33 stock positions worth $522.0 million. Its top holding was Urogen Pharma (URGN) at 9.3% of the portfolio, followed by Neurogene (NGNE, 7.0%) and Abivax SA-ADR (ABVX, 6.3%). Compared with Q1 2024, it opened 7 new positions, sold out of 9, added to 15 and reduced 8. The biggest buy was Merus (MRUS, shares +134%) and the biggest sale an exit from Alpine Immune Sciences (ALPN).
- Most Recent 13F
- Q2 2026
- Location
- Greenwich, CT
- CIK
- 0001281446
- Portfolio Value
- $522.0M (Q2 2024)
- SEC Filing
- 0001172661-24-003577 ↗ filed Aug 14, 2024
Holdings Value
Holdings 33 stocks · $522.0M
| URGN Urogen Pharma Ltd. | 9.34% | 2,906,259 | $48.8M | Add +10.9% |
| NGNE Neurogene Inc. | 7.00% | 1,004,291 | $36.5M | No change |
| ABVX Abivax SA-ADR | 6.26% | 2,472,188 | $32.7M | Reduce -0.7% |
| MRUS Merus NV | 5.93% | 523,288 | $31.0M | Add +134.4% |
| PLRX Pliant Therapeutics Inc. | 5.43% | 2,636,864 | $28.3M | Add +42.4% |
| ACLX Arcellx Inc. | 5.20% | 492,000 | $27.2M | Add +64.0% |
| DVAX Dynavax Technologies Corp. | 5.11% | 2,374,000 | $26.7M | Add +87.7% |
| EOLS Evolus Inc. | 5.10% | 2,451,772 | $26.6M | Add +0.1% |
| CYTK Cytokinetics Inc. | 4.92% | 474,202 | $25.7M | Add +134.5% |
| DNTH Dianthus Therapeutics Inc. | 3.76% | 757,929 | $19.6M | Add +21.3% |
| INSM Insmed Inc. | 3.21% | 250,000 | $16.8M | Reduce -67.8% |
| ZURA Zura Bio Ltd. | 3.11% | 4,642,241 | $16.2M | Add +68.3% |
| KALV Kalvista Pharmaceuticals Inc. | 3.02% | 1,338,568 | $15.8M | New |
| IONS Ionis Pharmaceuticals Inc. | 3.01% | 330,000 | $15.7M | New |
| CNTX Context Therapeutics Inc. | 2.85% | 7,419,355 | $14.9M | New |
| FOLD Amicus Therapeutics Inc. | 2.84% | 1,495,500 | $14.8M | No change |
| OPTINOSE INC | 2.73% | 13,727,097 | $14.3M | Add +56.2% |
| ESPR Esperion Therapeutics Inc. | 2.46% | 5,791,594 | $12.9M | Reduce -27.6% |
| VYGR Voyager Therapeutics Inc. | 2.43% | 1,601,527 | $12.7M | New |
| OTLK Outlook Therapeutics Inc. | 2.41% | 1,701,510 | $12.6M | Add +15.0% |
| AUTL Autolus Therapeutics PLC | 2.29% | 3,441,667 | $12.0M | Add +195.0% |
| JSPR Jasper Therapeutics Inc. | 1.75% | 402,015 | $9.1M | Reduce -1.4% |
| OLMA Olema Pharmaceuticals Inc. | 1.65% | 796,880 | $8.6M | New |
| TERN Terns Pharmaceuticals Inc. | 1.50% | 1,149,406 | $7.8M | Reduce -12.3% |
| VRDN Viridian Therapeutics Inc. | 1.25% | 500,000 | $6.5M | Reduce -62.5% |
| TCRX Tscan Therapeutics Inc. | 1.05% | 940,831 | $5.5M | New |
| VTGN Vistagen Therapeutics Inc. | 1.02% | 1,529,338 | $5.3M | Reduce -17.7% |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 0.98% | 500,000 | $5.1M | No change |
| PBYI Puma Biotechnology Inc. | 0.93% | 1,486,544 | $4.8M | Add +10.6% |
| KYTX Kyverna Therapeutics Inc. | 0.72% | 499,152 | $3.7M | Add +232.8% |
| SYRE Spyre Therapeutics Inc. | 0.61% | 134,612 | $3.2M | Add +7.7% |
| ANAB Anaptysbio Inc. | 0.12% | 25,000 | $627K | Reduce -97.4% |
| LXRX Lexicon Pharmaceuticals Inc. | 0.01% | 30,000 | $50K | New |
Portfolio Sells Q1 2024 → Q2 2024
| ALPN Alpine Immune Sciences Inc. | Sold out | 0.00% | −6.97 |
| APGE Apogee Therapeutics Inc. | Sold out | 0.00% | −4.14 |
| AEROVATE THERAPEUTICS INC | Sold out | 0.00% | −4.09 |
| ANAB Anaptysbio Inc. | Reduce -97.4% | 0.12% | −3.31 |
| XENE Xenon Pharmaceuticals Inc. | Sold out | 0.00% | −3.06 |
| MIND MEDICINE MINDMED INC | Sold out | 0.00% | −2.93 |
| OCUL Ocular Therapeutix Inc. | Sold out | 0.00% | −2.45 |
| VRDN Viridian Therapeutics Inc. | Reduce -62.5% | 1.25% | −2.40 |
| ITCI Intra-Cellular Therapies Inc. | Sold out | 0.00% | −1.62 |
| IMCR Immunocore Holdings PLC-ADR | Sold out | 0.00% | −1.17 |
| ESPR Esperion Therapeutics Inc. | Reduce -27.6% | 2.46% | −0.88 |
| VTGN Vistagen Therapeutics Inc. | Reduce -17.7% | 1.02% | −0.51 |
| ARVN Arvinas Inc. | Sold out | 0.00% | −0.46 |
| JSPR Jasper Therapeutics Inc. | Reduce -1.4% | 1.75% | −0.12 |
| INSM Insmed Inc. | Reduce -67.8% | 3.21% | −0.07 |
| TERN Terns Pharmaceuticals Inc. | Reduce -12.3% | 1.50% | +0.16 |
| ABVX Abivax SA-ADR | Reduce -0.7% | 6.26% | +0.71 |
Portfolio Buys Q1 2024 → Q2 2024
| MRUS Merus NV | Add +134.4% | 5.93% | +4.36 |
| URGN Urogen Pharma Ltd. | Add +10.9% | 9.34% | +3.22 |
| KALV Kalvista Pharmaceuticals Inc. | New | 3.02% | +3.02 |
| IONS Ionis Pharmaceuticals Inc. | New | 3.01% | +3.01 |
| CNTX Context Therapeutics Inc. | New | 2.85% | +2.85 |
| CYTK Cytokinetics Inc. | Add +134.5% | 4.92% | +2.71 |
| DVAX Dynavax Technologies Corp. | Add +87.7% | 5.11% | +2.66 |
| VYGR Voyager Therapeutics Inc. | New | 2.43% | +2.43 |
| ZURA Zura Bio Ltd. | Add +68.3% | 3.11% | +2.01 |
| ACLX Arcellx Inc. | Add +64.0% | 5.20% | +1.95 |
| OLMA Olema Pharmaceuticals Inc. | New | 1.65% | +1.65 |
| AUTL Autolus Therapeutics PLC | Add +195.0% | 2.29% | +1.13 |
| PLRX Pliant Therapeutics Inc. | Add +42.4% | 5.43% | +1.13 |
| TCRX Tscan Therapeutics Inc. | New | 1.05% | +1.05 |
| DNTH Dianthus Therapeutics Inc. | Add +21.3% | 3.76% | +0.84 |
| OPTINOSE INC | Add +56.2% | 2.73% | +0.74 |
| KYTX Kyverna Therapeutics Inc. | Add +232.8% | 0.72% | +0.14 |
| LXRX Lexicon Pharmaceuticals Inc. | New | 0.01% | +0.01 |
| SYRE Spyre Therapeutics Inc. | Add +7.7% | 0.61% | −0.13 |
| PBYI Puma Biotechnology Inc. | Add +10.6% | 0.93% | −0.18 |
| EOLS Evolus Inc. | Add +0.1% | 5.10% | −0.25 |
| OTLK Outlook Therapeutics Inc. | Add +15.0% | 2.41% | −0.35 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 37 | $424.4M | VOR, ABVX, VERA, ZURA, ALMS |
| Q1 2026 | 39 | $408.3M | APGE, VOR, ZURA, AMLX, NKTR |
| Q4 2025 | 29 | $308.4M | APGE, AMLX, ZURA, IRON, RAPT |
| Q3 2025 | 28 | $239.5M | AMLX, RZLT, NKTR, ZURA, SLNO |
| Q2 2025 | 26 | $153.8M | IONS, RZLT, AMLX, LEGN, ABVX |
| Q1 2025 | 31 | $184.0M | CYTK, KALV, EOLS, ABVX, VRDN |
| Q4 2024 | 26 | $212.2M | IONS, CYTK, KALV, VRDN, PLRX |
| Q3 2024 | 29 | $331.4M | NGNE, ABVX, PLRX, EOLS, VRDN |
| Q2 2024 | 33 | $522.0M | URGN, NGNE, ABVX, MRUS, PLRX |
| Q1 2024 | 35 | $641.6M | NGNE, ALPN, URGN, ABVX, EOLS |